Familial adenomatous polyposis in three generations of a single family: a case study

Murgić, Jure; Kirac, Iva; Soldić, Željko; Tomas, Davor; Zovak, Mario; Bolanča, Ante; Plawski, Andrzej; Banasiewicz, Tomasz; Kusić, Zvonko

Source / Izvornik: Case Reports in Oncology, 2014, 7, 349 - 356

Journal article, Published version Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

https://doi.org/10.1159/000363221

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:105:339713

Rights / Prava: In copyright/Zaštićeno autorskim pravom.

Download date / Datum preuzimanja: 2024-06-01



Repository / Repozitorij:

<u>Dr Med - University of Zagreb School of Medicine</u> <u>Digital Repository</u>





Case Rep Oncol 2014;7:349-356

DOI: 10.1159/000363221 Published online: May 28, 2014 © 2014 S. Karger AG, Basel 1662–6575/14/0072–0349\$39.50/0 www.karger.com/cro



This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.

Familial Adenomatous Polyposis in Three Generations of a Single Family: A Case Study

Jure Murgic^a Iva Kirac^b Zeljko Soldic^a Davor Tomas^c Mario Zovak^d Ante Bolanca^a Andrzej Plawski^e Tomasz Banasiewicz^f Zvonko Kusic^a

^aDepartment of Oncology and Nuclear Medicine, ^bDepartment of Surgical Oncology, University Hospital for Tumors, ^cLjudevit Jurak Department of Pathology and ^dDepartment of Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; ^eInstitute of Human Genetics, Polish Academy of Sciences, and ^fDepartment of General Surgery, Poznań University of Medical Sciences, Poznań, Poland

Key Words

Familial adenomatous polyposis · Rectal cancer · Colectomy · 2805C>G substitution

Abstract

Background: Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited syndrome characterized by the development of numerous polyps in the colon and rectum. If left untreated, the affected patients inevitably develop colon cancer by the age of 40 years. A resection of the colon (colectomy) or of the colon and rectum (proctocolectomy) is needed to minimize the risk of cancer. **Case Presentation:** We report a case of FAP through three generations of a single family, in which the grandmother and granddaughter underwent total colectomy with ileoanal anastomosis and did not develop colon cancer, while the son underwent subtotal colectomy with ileorectal anastomosis and developed recurrent rectal cancer. Data regarding timely surgery, surveillance, and chemoprevention are discussed. **Conclusion:** The FAP phenotype determines the type of treatment. In severe polyposis, proctocolectomy with ileoanal anastomosis seems to be the optimal method for minimizing the risk of cancer development. This case report advocates complete rectal removal, especially in cases of poor patient compliance with colonoscopic surveillance.

© 2014 S. Karger AG, Basel







Case Rep Oncol 2014;7:349–356	
	© 2014 S. Karger AG, Basel www.karger.com/cro

Background

Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited syndrome characterized by the development of numerous (hundreds to thousands) polyps in the epithelium of the large intestines [1]. Its prevalence is approximately 3–10/100,000, affecting both sexes equally, with symptoms clinically manifesting themselves by the late teens and in the twenties [2]. The syndrome has a strong penetrance and in a typical course, all patients develop colorectal cancer, except when they are diagnosed and treated at an early stage. These polyps start out as adenomas in childhood, predominantly in the rectosigmoid colon, and during the second and third decades of life a malignant transformation to colorectal cancer occurs. The most common symptoms manifest in the advanced stage of FAP and include rectal bleeding, anemia, abdominal pain, tenesmus, and diarrhea. In the majority of FAP patients, a genetic disorder resulting from a germline mutation in the adenomatous polyposis gene (*APC* gene) is responsible for the syndrome [3].

Other common clinical features in patients with FAP include multiple gastric fundic gland polyps, duodenal, periampullar or ampullar adenomas, while extraintestinal features are desmoid tumors, congenital hypertrophy of the retinal pigment epithelium, epidermoid cysts, osteomas and thyroid cancer [4].

Of all the colorectal cancer cases worldwide, FAP accounts for less than 1%. The majority of patients with FAP develop colorectal cancer by the age of 40 years. Therefore, different surgical strategies have been adopted to prevent cancer development in the large bowel mucosa. Herein we discuss these options based on a three-generation case.

Case Presentation

All surgical interventions, histology, extracolonic manifestations, and mutations recorded in the affected family members are presented in a timeline fashion in table 1.

Case 1

Based on colonoscopically confirmed multiple polyps in the colon and rectum at the age of 11 coupled with a family history, a male patient underwent subtotal colectomy with ileorectal anastomosis. At 39 years of age, the patient underwent restorative proctectomy with ileal pouch-anal anastomosis. Histopathology revealed hundreds of polyps with two adenocarcinomas found in the specimen – both Dukes A, Astler Coller B1 and G2 – and multiple polyps with low- to high-grade dysplasia (fig. 1, fig. 2). In 2010, at the age of 41, the patient was referred for genetic testing from the Oncology Department where he was receiving 5-fluoropirimidine/leucovorin and radiation as adjuvant treatment after Miles procedure for recurrent rectal cancer (a tumor 3 cm in diameter was found on ileoanal anastomosis, with 3 positive lymph nodes out of 4 isolated). The 2-year follow-up CT showed multiple lung and liver metastases and the patient was treated with a capecitabine-irinotecan (XELIRI) plus bevacizumab protocol as first-line chemotherapy for metastatic colorectal cancer.

Case 2

The first clinically confirmed family member was patient No. 1's mother. In 1972, the Caucasian female, who was 24 years old at the time, underwent her first procedure, which was Miles procedure for rectal cancer located at 13 cm from the anal verge. On pathology specimen, several polyps with high-grade dysplasia were found in the rectal ampulla. At the





Case Rep Oncol 2014;7:349–356	
	© 2014 S. Karger AG, Basel www.karger.com/cro

age of 33, a correction of sigmoidostomy was performed due to a prolapse of the stoma, and multiple polyps were found in the specimen. Clinical diagnosis of FAP was established. At the age of 42, total colectomy with Kock's reservoir was performed (around 50 polyps with low-to high-grade dysplasia were recorded on pathology report). Further follow-up was carried out according to FAP protocols, and at the age of 55, polyps were detected in the gastric antrum and duodenum and a biopsy revealed adenoma. At the age of 57, 4 large periampullar polyps were removed, one of which comprised adenocarcinoma in situ. At the age of 63 and 65, another 2 polyps, gastric and duodenal, were removed. At the age of 45, adenoma of the parathyroid had been removed.

Case 3

After the clinical diagnosis was established in the family, other family members were screened. In 2010, patient No. 1's 13-year-old daughter was routinely followed by colonoscopy. One year later, after high-grade dysplasia was confirmed by a polyp biopsy, total proctocolectomy with ileoanal anastomosis was performed (pathology examination of the specimen revealed more than 50 polyps, with one comprising adenocarcinoma in situ). In 2012, the patient underwent total thyroidectomy due to papillary thyroid cancer and duodenal polypectomy for duodenal tubular adenoma. No other extracolonic disease or intestinal recurrences were found.

The Family

Retrospectively, the family history revealed that patient No. 2's mother had had colon cancer at the age of 41 and that her father had died of gastric cancer at the age of 69. However, medical records could not be retrieved. Patient No. 1's 31-year-old brother and his older daughter (14 years old) had 2 and 3 polyps on colonoscopy, respectively (adenomas on biopsy), while his younger daughter (12 years old) had negative colonoscopy.

Mutations

A family pedigree chart (fig. 3) was then constructed and genetic testing was offered to the entire family: patients No. 1–3, patient No. 1's brother and his daughters. In patients No. 1–3, a 2805C>G substitution was detected. The mutation causes premature APC protein termination at the position 935Y>X. The other family members were mutation-free.

Discussion

Herein a three-generation case of FAP in a single family is presented, in which the grandmother, her son and her granddaughter had a clinical presentation of FAP. The grandmother and granddaughter remained disease-free after they had undergone total proctocolectomy, but the son developed recurrent colon cancer on ileoanal anastomosis and later metastatic disease. They were all subjected to the screening and follow-up recommended for FAP patients, and genetic testing revealed a 2805C>G substitution, which results in a truncated protein.

Most individuals with FAP will develop colon cancer by the age of 40; therefore, prophylactic surgery is generally recommended before the age of 25. There are 3 main surgical options for patients with FAP: (1) total proctocolectomy with Brooke ileostomy; (2) subtotal colectomy with ileorectal anastomosis, and (3) restorative proctocolectomy with the formation of an ileal reservoir and ileoanal anastomosis [5, 6]. The treatment of choice is total colectomy; however, the removal or preservation of the rectum is a matter of contro-





Case Rep Oncol 2014;7:349–356	
	© 2014 S. Karger AG, Basel www.karger.com/cro

versy. The decision to remove the rectum is influenced by the number of polyps in the rectum as well as by the family history. If there are only few polyps in the rectum, total colectomy with ileorectal anastomosis may be recommended. If the rectum is involved, then restorative proctocolectomy with ileal pouch-anal anastomosis is the treatment of choice [7]. Prophylactic surgery significantly improves the outcome of patients with FAP.

In the granddaughter's resected colon, numerous polyps were found, microscopically demonstrating high-grade epithelial dysplasia as the last stage in the multistep process of colorectal carcinogenesis. These features probably displayed a more aggressive mutation phenotype since she was only 14 years old at the time of surgery. Generally, prophylactic cancer-preventive colorectal surgery is recommended by the late teens or early twenties [8]. Half of FAP patients develop adenomas by 15 years of age but cancer development at this age is uncommon. Generally, cancer starts to develop a decade after the appearance of the polyps [9]. The optimal surgical procedure is proctocolectomy with pouch formation and ileoanal anastomosis since it completely removes all large bowel mucosa as potential origin of cancer and thereby minimizes the risk of malignancy, while preserving bowel function. For most patients, this is the procedure of choice [10]. On the other hand, patients who undergo ileorectal anastomosis are at risk, varying from 13 to 59%, of developing rectal adenomas and carcinomas after 25 years and they demand lifelong rectal surveillance [5]. Moreover, in a subset of patients having undergone proctocolectomy, endoscopic annual surveillance of the pouch and transitional anal zone is essential since many studies have demonstrated that premalignant changes and invasive adenocarcinomas are found in the ileoanal pouch even after restorative proctocolectomy [11–13].

Patient No. 1 omitted colonoscopic surveillance between the last two surgical procedures, which might explain the extent of local recurrence. Colonoscopy and prophylactic colectomy are the primary strategies to prevent colon cancer or detect it at an early stage. The American Gastroenterology Association recommends annual sigmoidoscopy in patients with classic FAP and at-risk relatives starting at the age of 10–12 years. Patients with adenomatous polyps found on sigmoidoscopy should undergo a full colonoscopy and random biopsies to establish the severity of the polyposis [14]. The family members who are mutation-free will be surveyed by the protocols for the general population. Implementation of genetic testing that would result in standard protocols is still a matter of debate, since the tests are still not widely available and patients are not referred when indicated, leaving room for improvement in FAP treatment.

The reason why the grandmother did not have a regular follow-up or a more aggressive surgical treatment remained obscure even after a careful review of her history. We believe it might both be due to the unawareness of this syndrome at the time of the first operation and surgery planning based on sigmoidoscopy. On the other hand, the patient had not been compliant with regular follow-up until the diagnosis of FAP was made and its implication explained. This issue stresses the critical importance of lifelong follow-up and responsibility for both patients and physicians to adhere to when dealing with FAP. Several studies have demonstrated that a regular use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors can reduce the polyp number and size in patients with FAP [15–17]. Upon these results, celecoxib was approved as adjunctive preventive treatment in patients with FAP, besides inevitable endoscopic surveillance and surgical intervention. The successful management of colonic disease implies a continuous surveillance of extracolonic disease. Patient No. 2 had surgery for parathyroid adenoma and patient No. 3 for thyroid cancer, while patient No. 2 had ampullar cancer endoscopically removed. Multidisciplinarity and, again, long-term surveillance is essential for these patients.



Case Rep Oncol 2014;7:349–356	
DOI: 10.1159/000363221	© 2014 S. Karger AG, Basel www.karger.com/cro

Conclusion

Patient compliance with regular and strict surveillance is an important factor when deciding on the optimal type of prophylactic surgery. Patients who are not adherent to surveillance should undergo proctocolectomy with ileal pouch-anal anastomosis. Timing and type of preventive surgery as well as compliance with preventive strategies and strict follow-up are essential for minimizing the risk of cancer development in patients with FAP.

References

- 1 Rosai J: Rosai and Ackerman's Surgical Pathology, ed 9. St. Louis, CV Mosby, 2004.
- 2 Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis 2009;12:4–22.
- 3 Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J: Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121–125.
- 4 Anaya DA, Chang GJ, Rodriguez-Bigas MA: Extracolonic manifestations of hereditary colorectal cancer syndromes. Clin Colon Rectal Surg 2008;21:263–372.
- 5 Aziz O, Athanasiou T, Fazio VW, Nicholls RJ, Darzi AW, Church J, Phillips RK, Tekkis PP: Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2006;93:407–417.
- 6 Bülow C, Vasen H, Järvinen H, Björk J, Bisgaard ML, Bülow S: Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 2000;119:1454–1460.
- 7 Ziv Y, Church JM, Oakley JR, McGannon E, Schroeder TK, Fazio VF: Results after restorative proctocolectomy and ileal pouch anal anastomosis in patients with familial adenomatous polyposis and coexisting colorectal cancer. Br J Surg 1996;83:1578–1580.
- 8 Phillips RKS, Spigelman AD: Can we safely delay or avoid prophylactic colectomy in familial adenomatous polyposis? Br J Surg 1996;83:769–770.
- 9 Petersen GM, Slack J, Nakamura Y: Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991;100:1658–1664.
- 10 Campbell AJ, Spence RAJ, Park TG: Familial adenomatous polyposis. Br J Surg 1994;81:1722–1733.
- 11 Parc YR, Olschwang S, Desaint B, Schmitt G, Parc RG, Tiret E: Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 2001;233:360–364.
- Hurlstone DP, Saunders BP, Church JM: Endoscopic surveillance of the ileoanal pouch following restorative proctocolectomy for familial adenomatous polyposis. Endoscopy 2008;40:437–442.
- 13 Ooi BS, Remzi FH, Gramlich T, Church JM, Preen M, Fazio VW: Anal transitional zone cancer after restorative proctocolectomy and ileoanal anastomosis in familial adenomatous polyposis: report of two cases. Dis Colon Rectum 2003;46:1418–1423.
- Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C; Gastrointestinal Consortium Panel: Colorectal cancer screening and surveillance: clinical guidelines and rationale update based on new evidence. Gastroenterology 2003;124:544–560.
- 15 Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641–645.
- Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–1316.
- 17 Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.





Case Rep Oncol 2014;7:349–356	
DOI: 10.1159/000363221	© 2014 S. Karger AG, Basel www.karger.com/cro

Table 1. Timeline of surgical interventions for the affected family members


	Case 2 (grandmother)	Case 1 (son)	Case 3 (granddaughter)
Age at diagnosis (years)	24	11	13
First procedure	At 24 years abdominoperineal resection; histology: rectal adenocarcinoma with few polyps	At 11 years subtotal colectomy with ileorectal anastomosis; histology: multiple polyps	At 14 years total proctocolectomy with ileoanal anastomosis; histology: FAP, countless polyps with high-grade dysplasia and one carcinoma in situ
Second procedure	At 33 years correction of sigmoidostomy for prolapse; histology: few polyps	At 39 years restorative proctectomy with ileal pouch-anal anastomosis; histology: multiple polyps with high-grade dysplasia; two adenocarcinomas (T2N0Mx G2, T1N0Mx G2)	-
Third procedure	At 42 years total colectomy with Kock's reservoir; histology: colon polyposis with numerous tubulovilluos adenomas with high-grade dysplasia	At 41 years abdominoperineal resection; histology: recurrent rectal adenocarcinoma (LNR 3/4) followed by RT/5FU/L	-
Extra-colonic disease	At 45 years adenoma of parathyroid was removed; histology: parathyroid adenoma At 55 years duodenal polypectomy; histology: adenovillous polyp At 57 years duodenal polypectomy; histology: villous adenoma with adenocarcinoma At 63 years gastric polyp; histology: adenomatous polyp with high-grade dysplasia At 65 years duodenal polyp; histology: adenomatous polyp	At 43 years progression with multiple liver and lung metastases followed by XELIRI-bevacizumab chemotherapy	At 15 years total thyroidectomy; histology: papillary thyroid cancer At 15 years polypectomy of duodenal polyp; histology: tubular adenoma

Genetic testing in all three patients revealed a 2805C>G substitution. LNR = Lymph node ratio; RT/5FU/L = radiotherapy concomitantly with 5-FU and leucovorin chemotherapy; XELIRI = capecitabine plus irinotecan.





Case Rep Oncol 2014;7:349–356		
		© 2014 S. Karger AG, Basel
		www.karger.com/cro



 $\textbf{Fig. 1.} \ \textbf{Countless polyps carpeting the mucosal surface of the resected rectum.}$




Fig. 2. a Villous adenoma with high-grade epithelial dysplasia (HE. \times 40). **b** Adenocarcinoma infiltrating the submucosa (HE. \times 40).



Case Rep Oncol 2014;7:349–356	
DOI: 10.1159/000363221	© 2014 S. Karger AG, Basel www.karger.com/cro




Fig. 3. Family pedigree chart.